Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of drug resistance in HIV-1 patients receiving a combination of stavudine, lamivudine and efavirenz.

International journal of antimicrobial agents - 1 Sept 2002

Re M C, Monari P, Bon I, Borderi M, Gibellini D, Schiavone P, Vitone F, Furlini G, La Placa M

Abstract excerpt

The study evaluated the development of drug resistance in a group of HIV-1 patients. After failure to respond to previous therapy with two non-nucleoside reverse transcriptase inhibitors (NNRTIs), as assessed by the presence of a rebound in viral load or a constant high level of HIV plasma viraemia, the patients were treated with a combination of stavudine, lamivudine and efavirenz (EFV). Results showed that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkynes
Share to Benzoxazines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclopropanes

Share to Genes, Viral

Share to Lamivudine

Share to Oxazines

Share to Stavudine

Share to Viremia

Source

Identifiers

PMID: 12385703
DOI: 10.1016/s0924-8579(02)00164-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of drug resistance in HIV-1 patients receiving a combination of stavudine, lamivudine and efavirenz.PMID 12385703Read ↗

Primary drug-resistance in HIV-positive patients on initiation of first-line antiretroviral therapy in Germany.Semantic proximity Read ↗

Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.Semantic proximity Read ↗

Persistence of earlier HIV-1 drug resistance mutations at new treatment failure.Semantic proximity Read ↗

HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen.Semantic proximity Read ↗

Phenotypic HIV-1 resistance correlates with treatment outcome of nelfinavir salvage therapy.Semantic proximity Read ↗

Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.Semantic proximity Read ↗

Detection of drug resistance mutations as a predictor of subsequent virological failure in patients with HIV-1 viral rebounds of less than 1,000 RNA copies/ml.Semantic proximity Read ↗

Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine.Semantic proximity Read ↗

Genotypic resistance profile in treatment-experienced HIV-infected individuals after abacavir and efavirenz salvage regimen.Semantic proximity Read ↗

Resistance analyses in HIV infected patients with a history of multiple antiretroviral treatment regimens.Semantic proximity Read ↗

Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients.Semantic proximity Read ↗

Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.